Morepen Laboratories net profit up 189%

R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices

Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Morepen to launch new fatty lever drug ‘Resmetirom’

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health